Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia

Molecular Psychiatry

Volumn 6, Issue 2, 2001, Pages 225-229

  Segman, R H ^a   Heresco Levy, U ^b   Finkel, B ^c   Goltser, T ^a   Shalem, R ^a   Schlafman, M ^d   Dorevitch, A ^e   Yakir, A ^a   Greenberg, D ^b   Lerner, A ^c   Lerer, B ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HERZOG HOSPITAL   (Israel)

^c HASHARON HOSPITAL   (Israel)

^d Kfar Shaul Hospital   (Israel)

^e Talbieh Hospital   (Israel)

Author keywords

5 HT2A; Genetic association; Schizophrenia; Serotonin receptors; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INDUCED DISEASE; ETHNIC GROUP; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; SCHIZOPHRENIA; SCORING SYSTEM; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DYSKINESIA, DRUG-INDUCED; FEMALE; GENETIC MARKERS; HUMANS; MALE; MIDDLE AGED; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SCHIZOPHRENIA;

EID: 17744392199     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000842     Document Type: Article

References (46)

1. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979
2. The role of serotenin in antipsychetic drug action
3. An Mspl polymorphism in the human serotonin receptor gene: Detection by DGGE and RFLP analysis
4. Two naturally occurring amino acid substitutions of the 5-HT2A receptor: Similar prevalence in patients with seasonal affective disorder and controls
5. Association between 5-HT2A gene promoter polymorphism and anorexia nervosa
6. Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia
7. The effect of haloperidol feeding on dopamine receptor number in ten mouse strains
8. Possible genetic factors underlying the pathophysiology of tardive dyskinesia
9. Tardive dyskinesia and ethnicity: Review of the literature
10. Familial occurrence of tardive dyskinesia
11. Genotypic association between the dopamine D3 receptor gene and tardive dyskinesia in chronic schizophrenia
12. Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients
13. Association of the Mscl polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
14. Homozygosity for Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients
15. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia
16. Clozapine in tardive dyskinesia: Observations from human and animal model studies
17. Expected incidence of tardive dyskinesia associated with atypical antipsychotics
18. [3H]ketanserin binding in human brain postmortem
19. The role of 5-HT2A receptors in antipsychotic activity
20. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain
21. Implications of amphetamine induced stereotyped behavior as a model for tardive dyskinesia
22. The effect of novel antipsychotics in rat oral dyskinesia
23. Subthalamic nucleus microinjections of 5-HT2 receptor antagonists suppress stereotypy in rats
24. Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain
25. The serotonin receptor subtype 2 locus HTR2 is on chromosome 13 near genes for estherase D and retinoblastoma and on mouse chromosome 14
26. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia
27. Analysis of the 5′-flanking promoter region of the 5-HT2A receptor gene in schizophrenia
28. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter
29. Association between allele 1 of T102C polymorphism, 5-hydroxytryptamine 2a receptor gene and schizophrenia in Chinese males in Singapore
30. No association or linkage between the 5-HT2a/T102C polymorphism and schizophrenia in Irish families
31. No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia
32. Schizophrenia and the serotonin-2A receptor promoter polymorphism
33. Negative association between T102C polymorphism of the 5-HT2a receptor gene and schizophrenia in Japan
34. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response
35. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients
36. Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine
37. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in post-mortem brain samples from subjects who did or did not commit suicide
38. 5-HT2A receptor gene polymorphism in anorexia nervosa and bulimia nervosa
39. Extrapyramidal syndromes in nearoleptic-treated patients: Prevalence risk factors and association with tardive dyskinesia
40. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: A prospective longitudinal study
41. Topographic subtypes of TD in schizophrenic patients aged less than 60 years: Relationship to demographic clinical treatment and neuropsychological variables
42. Heterogeneity of tardive dyskinesia. A multivariate analysis
43. Research diagnoses for tardive dyskinesia
44. A rating scale for extrapyramidal side effects